Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis

Table 2 Summary of the trials examined T

Study year	Intervention	Bisphosphonate acid administration	Combination therapy	Duration (y)	No. patients per arm	Follow-up (months)
ABCSG-12 (2011) [15]	Zoledronic acid Observation	4 mg IV every 6 mos	Goserelin and Tamoxifen or Anastrozole	3	900	62
ABCSG-12 (2011) [15]	Zoledronic acid Observation	4 mg IV every 6 mos	Goserelin and Tamoxifen or Anastrozole	3	903	62
AZURE (2011) [14]	Zoledronic acid Observation	4 mg IV every 4 wks × 6, then 3 mos × 8 and 6 mos × 5	Standard treatment	5	1681	59
AZURE (2011) [14]	Zoledronic acid Observation	4 mg IV every 4 wks × 6, then 3 mos × 8 and 6 mos × 5	Standard treatment	5	1678	59
E-ZO-FAST (2009) [20]	Upfront zol	4 mg IV every 6 mos	Letrozol	5	263	36
E-ZO-FAST (2009) [20]	Delayed zol	4 mg IV every 6 mos			264	36
Z-FAST (2012) [17]	Upfront zol	4 mg IV every 6 mos	Letrozol	5	300	61
Z-FAST (2012) [17]	Delayed zol	4 mg IV every 6 mos			300	61
ZO-FAST (2013) [16]	Upfront zol	4 mg IV every 6 mos	Letrozol	5	532	60
ZO-FAST (2013) [16]	Delayed zol	4 mg IV every 6 mos			533	60
Talahashi et al., (2013) [21]	Upfront zol	4 mg IV every 6 mos	Letrozol	1	94	36
Talahashi et al., (2013) [21]	Delayed zol	4 mg IV every 6 mos			95	36
Leal et al., (2010) [19]	Zoledronic acid Observation	4 mg IV every 3 mos	Standard treatment	1	36	96
Leal et al., (2010) [19]	Zoledronic acid Observation	4 mg IV every 3 mos	Standard treatment	1	32	96
Aft et al., (2012) [18]	Zoledronic acid Observation	4 mg IV every 3 wks	Neoadjuvant chemotherapy		60	61.9
Aft et al., (2012) [18]	Zoledronic acid Observation	4 mg IV every 3 wks	Neoadjuvant chemotherapy		59	61.9